Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372244 | 1.00 | ADRB2 (1.00) | ADRB2 | |
| Bromide SCHEMBL523612 | 0.99 | ADRB2 (1.00) | ADRB2 | |
| Hydrochloric Acid SCHEMBL1320905 | 0.99 | ADRB2 (0.99) | ADRB2 | |
| Bromide SCHEMBL1289957 | 0.99 | ADRB2 (1.00) | ADRB2 | |
| Phosphoric Acid SCHEMBL1321143 | 0.98 | ADRB2 (0.96) | ADRB2 | |
| Sulfuric Acid SCHEMBL1322299 | 0.97 | ADRB2 (0.95) | ADRB2 | |
| Citric Acid SCHEMBL1322178 | 0.93 | ADRB2 (0.86) | ADRB2 | |
| SCHEMBL3590466 | 0.90 | ADRB2 (0.82) | ADRB2 | |
| SCHEMBL1321145 | 0.90 | ADRB2 (0.81) | ADRB2 | |
| SCHEMBL3592448 | 0.89 | ADRB2 (1.00) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448623-B1 | DISPENSER AND METHOD FOR ENTRAINING POWDER IN AN AIRFLOW | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | claimed |
| US-9289565-B2 | Inhaler with indexing linked to movement of cover | ASTRAZENECA AB (SE) | 2016-03-22 | — | — | US | claimed |
| EP-2334358-B1 | INHALATION DEVICE FOR DISPENSING MEDICAMENT | ASTRAZENECA AB (SE) | 2016-02-10 | — | — | EP | claimed |
| US-9155851-B2 | Breath activated inhaler | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | claimed |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA UK LIMITED (GB) | 2015-05-21 | — | — | US | claimed |
| EP-2595683-B1 | Inhaler | ASTRAZENECA AB (SE) | 2015-03-04 | — | — | EP | claimed |
| US-20140083422-A1 | INHALER | ASTRAZENECA AB | 2014-03-27 | — | — | US | claimed |
| US-8578933-B2 | Entraining powder in an airflow | ASTRAZENECA AB (SE) | 2013-11-12 | — | — | US | claimed |
| EP-2595683-A2 | INHALER | AstraZeneca AB (SE) | 2013-05-29 | — | — | EP | claimed |
| US-20130112194-A1 | PROCESS FOR PROVIDING A FILLED CANISTER FOR AN INHALER | ASTRAZENECA UK LIMITED (GB) | 2013-05-09 | — | — | US | claimed |
| WO-2009142568-A1 | COMBINATION OF (A) GLUCOCORTICOID RECEPTOR MODULATOR AND (B) A B2-AGONIST | ASTRAZENECA AB (SE) | 2009-11-26 | — | — | WO | claimed |
| EP-2120935-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | claimed |
| WO-2009139708-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | claimed |
| EP-2117542-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | AstraZeneca AB (SE) | 2009-11-18 | — | — | EP | claimed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | claimed |
| US-20080249145-A1 | Salts 668 | ASTRAZENECA AB (SE) | 2008-10-09 | — | — | US | claimed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | claimed |
| WO-2008103126-A1 | NOVEL COMBINATION OF COMPOUNDS TO BE USED IN THE TREATMENT OF AIRWAY DISEASES, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND ASTHMA | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | WO | claimed |
| WO-2008096126-A1 | COMBINATION OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | ARGENTA DISCOVERY LTD (GB) | 2008-08-14 | — | — | WO | claimed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249145-A1 | Salts 668 | DNPEP, SCN8A, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | ADRB2 57/4885 |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | ADRB2 156/4885 |
| US-20150141387-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | NR3C2, GRK4, PTGER2 | ADRB2 34/4885 |
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | ADRB2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.